Alpha blockers and 5-alpha reductase inhibitors increase the risk of ejaculatory dysfunction, a systematic review and meta-analysis shows.
New study also suggests that low preoperative hematocrit and albumin levels predict adverse outcomes.
Cumulative rates of clinical success were 87.2% at 3 months, 80.2% at 18 months, and 72.3% at 36 months (long term).
Older and obese men and those with low HDL cholesterol are more likely to have the syndrome as a determinant of prostatic enlargement.
Early results from a small group of patients show a clinical success rate of 95%.
The FDA has approved the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with BPH.
Improvements observed in urinary symptoms and bone mineral density.
Men with a body mass index of 30 kg/m2 or higher had a 39.3% prevalence of low testosterone, study finds.
Adding ketoconazole to tamsulosin increased the likelihood of a successful trial without catheter in men with benign prostatic obstruction.
Lower urinary tract symptoms (LUTS) are commonly attributed to benign prostatic hyperplasia.
BPH has long been thought to be an inevitable function of genetic predisposition and age related changes in sex steroid hormones.
The incidence of emergency department visits rose 36% from 2007 to 2010 in California.
Alpha blockers are the mostly commonly prescribed drugs to treat LUTS secondary to BPH.
No evidence of toxicity for patients given doses of up to 960 mg daily for up to 18 months.
The drug increases the likelihood of a successful trial without catheter.